What Proto Labs (PRLB) Guidance Raise Means For Its Valuation

Proto Labs (PRLB) is back in focus after reporting record second quarter revenue and roughly doubling net income year over year, alongside higher full year revenue growth guidance and a firmer third quarter outlook.

See our latest analysis for Proto Labs.

The latest earnings and guidance have come after a strong run in Proto Labs’ share price, with a year to date share price return of 46.15% and a 1 year total shareholder return of 73.77%. This points to building momentum despite a recent 30 day share price pullback of 4.69%.

If this kind of move has your attention, it can be a good moment to broaden your search and check out our screener of 36 robotics and automation stocks

Proto Labs now sits between a bullish story of improving earnings and guidance, and a bearish view that the share price has already run hard. Which side does the current valuation evidence support next in this article?

Most Popular Narrative: 14.7% Undervalued

The most followed Proto Labs narrative points to a fair value of $88 per share, compared to the last close at $75.05, which suggests meaningful upside potential based on those assumptions.

Proto Labs is experiencing strong momentum in its CNC machining and sheet metal capabilities, especially driven by demand from Aerospace & Defense clients and expansion of high-requirement, production-focused offerings. This is poised to drive sustained revenue growth, particularly as mass customization and the need for agile, small-volume production expand.

Read the complete narrative.

Curious how this story gets to a higher fair value for Proto Labs. It leans heavily on steady growth, wider margins, and a richer future earnings multiple.

Result: Fair Value of $88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Proto Labs story also carries real risks, including dependence on a small group of large customers and ongoing weakness in European manufacturing that could hinder growth.

Find out about the key risks to this Proto Labs narrative.

Another View: Proto Labs Through A DCF Lens

The popular Proto Labs narrative leans on a fair value of $88 per share and sees the stock as 14.7% undervalued. Our DCF model tells a different story. On those cash flow assumptions, Proto Labs is trading above an estimated value of $55.98, which implies it could be overvalued.

For investors, that split between an $88 fair value and a $55.98 DCF estimate raises a simple question: Which set of assumptions feels closer to how Proto Labs can actually perform over time, and which one are you more comfortable backing with your own capital?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Proto Labs for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Reading through the mixed sentiment on Proto Labs, it makes sense to review the underlying data yourself, consider both sides, and assess how the company fits your portfolio using 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Proto Labs?

If Proto Labs has sharpened your focus, now is the time to widen your watchlist and uncover other opportunities that could fit your style before others do.

• Target resilient income by reviewing companies in the 9 dividend fortresses and see which ones align with your cash flow goals.
• Zero in on quality at a sensible price by checking the 55 high quality undervalued stocks that pair fundamentals with attractive valuations.
• Spot potential future standouts early by scanning the screener containing 19 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com